FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity | FDA

FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity | FDA

FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity

The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc., used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled medicine. NDMA is classified as a probable human carcinogen (a substance that could cause cancer).

• Read More About Recall